[go: up one dir, main page]

MX2009002740A - Inhibidores de renina. - Google Patents

Inhibidores de renina.

Info

Publication number
MX2009002740A
MX2009002740A MX2009002740A MX2009002740A MX2009002740A MX 2009002740 A MX2009002740 A MX 2009002740A MX 2009002740 A MX2009002740 A MX 2009002740A MX 2009002740 A MX2009002740 A MX 2009002740A MX 2009002740 A MX2009002740 A MX 2009002740A
Authority
MX
Mexico
Prior art keywords
aspartic protease
protease inhibitors
aspartic
directed
subject
Prior art date
Application number
MX2009002740A
Other languages
English (en)
Inventor
John J Baldwin
David A Claremon
Colin M Tice
Wei Zhao
Salvacion Cacatian
Lawrence W Dillard
Alexey V Ishchenko
Jing Yuan
Zhenrong Xu
Gerard Mcgeehan
Robert D Simpson
Suresh B Singh
Lanqi Jia
Patrick T Flaherty
Original Assignee
Vitae Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38786973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009002740(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc
Publication of MX2009002740A publication Critical patent/MX2009002740A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a inhibidores de proteasas aspárticas representados por la siguiente fórmula estructural (I), o una sal farmacéuticamente aceptable de los mismos. La presente invención también se refiere a composiciones farmacéuticas que comprenden los inhibidores de proteasas aspárticas de la Fórmula Estructural (I). También se describen métodos para antagonizar una o más proteasas aspárticas en un sujeto en necesidad de lo mismo, y métodos para tratar un trastorno mediado por proteasas aspárticas en un sujeto usando estos inhibidores de proteasas aspárticas.
MX2009002740A 2006-09-18 2007-09-18 Inhibidores de renina. MX2009002740A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84529106P 2006-09-18 2006-09-18
PCT/US2007/020164 WO2008036247A1 (en) 2006-09-18 2007-09-18 Renin inhibitors

Publications (1)

Publication Number Publication Date
MX2009002740A true MX2009002740A (es) 2009-06-26

Family

ID=38786973

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002740A MX2009002740A (es) 2006-09-18 2007-09-18 Inhibidores de renina.

Country Status (22)

Country Link
US (2) US8198453B2 (es)
EP (2) EP2074108B3 (es)
JP (1) JP5331695B2 (es)
KR (1) KR20090064582A (es)
CN (1) CN101528723B (es)
AR (1) AR062797A1 (es)
AU (1) AU2007297729C1 (es)
BR (1) BRPI0718460A2 (es)
CA (1) CA2663263A1 (es)
CL (1) CL2007002689A1 (es)
DK (1) DK2074108T3 (es)
ES (1) ES2400009T7 (es)
HR (1) HRP20130144T4 (es)
MX (1) MX2009002740A (es)
NZ (1) NZ575803A (es)
PE (1) PE20080843A1 (es)
PL (1) PL2074108T6 (es)
PT (1) PT2074108E (es)
RS (1) RS52679B (es)
SI (1) SI2074108T1 (es)
TW (1) TWI403510B (es)
WO (1) WO2008036247A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0516132A (pt) * 2004-10-07 2007-12-04 Vitae Pharmaceuticals Inc compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
US20090318501A1 (en) * 2006-09-18 2009-12-24 Baldwin John J Piperidine derivatives as renin inhibitors
EP2167609A1 (en) * 2007-06-20 2010-03-31 Vitae Pharmaceuticals, Inc. Renin inhibitors
US20100160424A1 (en) * 2007-06-20 2010-06-24 Baldwin John J Renin inhibitors
US20110160300A1 (en) * 2008-06-20 2011-06-30 Marlys Hammond Renin Inhibitors and Methods of Use Thereof
CN102088850A (zh) * 2008-06-26 2011-06-08 生命医药公司 甲基2-((r)-(3-氯苯基)((r)-1-((s)-2-(甲氨基)-3((r)-四氢-2h-吡喃-3-基)丙基氨甲酰基)哌啶-3-基)甲氧基)氨基甲酸乙酯的盐
US20100010228A1 (en) * 2008-06-26 2010-01-14 Vitae Pharmaceuticals, Inc. Process for the asymmetric reduction of 3-benzoylpiperidines
AU2013248242B2 (en) * 2009-03-18 2016-08-18 Incarda Therapeutics, Inc Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2016256776B2 (en) * 2009-03-18 2018-04-12 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP3552602B1 (en) 2009-03-18 2025-03-05 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AR077692A1 (es) * 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
KR20180102201A (ko) 2016-02-01 2018-09-14 인카다 테라퓨틱스, 인크. 심방 세동을 포함한 심장 부정맥을 관리하기 위한 전자 모니터링과 흡입 약리 치료의 조합
JP2020519628A (ja) 2017-05-10 2020-07-02 インカーダ セラピューティクス， インコーポレイテッド 肺投与によって心臓の状態を処置するための単位用量、エアロゾル、キットおよび方法
ES3040411T3 (en) 2018-03-22 2025-10-30 Incarda Therapeutics Inc A novel method to slow ventricular rate
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
CN117567292B (zh) * 2023-12-01 2026-01-16 江苏宝众宝达药业股份有限公司 一种制备高纯度5-氯-2-甲基苯胺的方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3071618A (en) * 1956-02-02 1963-01-01 Pfizer & Co C Diquaternary ammonium salts of n, n, n', n'-tetra substituted alkylene diamines
US4136163A (en) * 1971-02-04 1979-01-23 Wilkinson Sword Limited P-menthane carboxamides having a physiological cooling effect
GB1351761A (en) 1971-02-04 1974-05-01 Wilkinson Sword Ltd Substituted p-menthane carboxamides and compositions containing them
JPS5115098A (ja) 1974-07-26 1976-02-06 Asahi Chemical Ind Akurirukeiseniseihinno shorihoho
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4594343A (en) 1984-10-19 1986-06-10 Shanklin Jr James R 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
GB8810067D0 (en) * 1988-04-28 1988-06-02 Ucb Sa Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US4908372A (en) * 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
DK0527879T3 (da) 1990-05-11 1997-07-14 Pfizer Synergistiske terapeutiske præparater og fremgangsmåder.
DE4018070A1 (de) * 1990-06-06 1991-12-12 Bayer Ag Morpholinoharnstoff-derivate
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
EP0561973A1 (en) * 1990-12-14 1993-09-29 Merrell Dow Pharmaceuticals Inc. Antiallergic compounds
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0626968B1 (en) * 1992-02-13 2001-09-26 Merrell Pharmaceuticals Inc. Piperidinyl thiacyclic derivatives
DK0644755T3 (da) 1992-06-10 1997-09-22 Nanosystems Llc Overflademodificerede NSAID-nanopartikler
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
JPH10503772A (ja) 1994-07-29 1998-04-07 アボツト・ラボラトリーズ 置換２，５−ジアミノ−３−ヒドロキシヘキサンの製造方法
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US6162927A (en) * 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US6946481B1 (en) * 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
CZ292327B6 (cs) 1995-09-07 2003-09-17 F. Hoffmann-La Roche Ag Derivát 4-(oxyalkoxyfenyl)-3-oxypiperidinu, způsob jeho přípravy, meziprodukt pro jeho přípravu a farmaceutický prostředek, který ho obsahuje
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
WO1998054179A1 (en) 1997-05-29 1998-12-03 Eli Lilly And Company Process for preparing heterocyclic compounds
AU3716499A (en) 1998-04-21 1999-11-08 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
GB9826540D0 (en) * 1998-12-02 1999-01-27 Darwin Discovery Ltd Process
ATE322483T1 (de) 1999-01-06 2006-04-15 Us Gov Health & Human Serv Inhibitoren für asparagin-proteasen
JP2000302757A (ja) 1999-04-16 2000-10-31 Shiseido Co Ltd Ｎ−置換ピペリジン誘導体
EA005893B1 (ru) * 2000-03-21 2005-06-30 Смитклайн Бичам Корпорейшн Ингибиторы протеаз
US6900329B2 (en) * 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
EA200400162A1 (ru) 2001-07-11 2005-06-30 Элан Фармасьютикалз, Инк. N-(3-амино-2-гидроксипропил)замещенные алкиламидные соединения
IL161881A0 (en) 2001-11-08 2005-11-20 Upjohn Co N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
CN101074242A (zh) 2002-04-26 2007-11-21 吉里德科学公司 Hiv蛋白酶抑制剂化合物的膦酸酯类似物的细胞蓄积及这类化合物
AU2003238046A1 (en) 2002-06-27 2004-01-19 Actelion Pharmaceuticals Ltd Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
US7557137B2 (en) * 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
JP2005538177A (ja) 2002-09-10 2005-12-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー アルツハイマー病処置用置換アミノエーテル化合物
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CN1890239A (zh) * 2003-12-05 2007-01-03 埃科特莱茵药品有限公司 二氮杂二环壬烯及带有新的侧链的四氢吡啶衍生物
US20070093492A1 (en) * 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
JP2008510726A (ja) 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
BRPI0516132A (pt) * 2004-10-07 2007-12-04 Vitae Pharmaceuticals Inc compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
ATE514697T1 (de) * 2005-01-28 2011-07-15 Actelion Pharmaceuticals Ltd 7-ä4-ä2-(2,6-dichloro-4- methylphenoxy)ethoxyüphenylü-3,9- diazabicycloä3.3.1ünon-6-ene-6-carbonsäure- cyclopropyl-(2,3-dimethylbenzyl)amid als renin- hemmer für die behandlung von bluthochdruck
WO2006083924A1 (en) * 2005-02-02 2006-08-10 Vitae Pharmaceuticals, Inc. 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
DK1882684T3 (en) 2005-05-19 2015-01-05 Astellas Pharma Inc PYRROLIDE INGREDIENTS OR SALTS THEREOF
TWI411607B (zh) * 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
WO2007117557A2 (en) 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
US20090318501A1 (en) * 2006-09-18 2009-12-24 Baldwin John J Piperidine derivatives as renin inhibitors
US20100160424A1 (en) * 2007-06-20 2010-06-24 Baldwin John J Renin inhibitors
EP2167609A1 (en) * 2007-06-20 2010-03-31 Vitae Pharmaceuticals, Inc. Renin inhibitors
US7773441B2 (en) * 2008-06-18 2010-08-10 Micron Technology, Inc. Memory malfunction prediction system and method
US20110160300A1 (en) 2008-06-20 2011-06-30 Marlys Hammond Renin Inhibitors and Methods of Use Thereof
CN102088850A (zh) 2008-06-26 2011-06-08 生命医药公司 甲基2-((r)-(3-氯苯基)((r)-1-((s)-2-(甲氨基)-3((r)-四氢-2h-吡喃-3-基)丙基氨甲酰基)哌啶-3-基)甲氧基)氨基甲酸乙酯的盐
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo

Also Published As

Publication number Publication date
PL2074108T3 (pl) 2013-05-31
TW200829574A (en) 2008-07-16
JP5331695B2 (ja) 2013-10-30
PT2074108E (pt) 2013-03-07
TWI403510B (zh) 2013-08-01
US8580823B2 (en) 2013-11-12
CA2663263A1 (en) 2008-03-27
AU2007297729C1 (en) 2012-02-02
ES2400009T7 (es) 2013-11-18
US20090312369A1 (en) 2009-12-17
DK2074108T3 (da) 2013-03-11
JP2010503684A (ja) 2010-02-04
PE20080843A1 (es) 2008-08-11
BRPI0718460A2 (pt) 2013-12-03
HRP20130144T1 (en) 2013-03-31
EP2074108B1 (en) 2012-11-21
NZ575803A (en) 2011-11-25
AR062797A1 (es) 2008-12-03
HK1129115A1 (en) 2009-11-20
WO2008036247A1 (en) 2008-03-27
US8198453B2 (en) 2012-06-12
KR20090064582A (ko) 2009-06-19
CL2007002689A1 (es) 2008-04-18
PL2074108T6 (pl) 2013-11-29
EP2074108A1 (en) 2009-07-01
AU2007297729B2 (en) 2011-07-28
HRP20130144T4 (hr) 2013-10-25
CN101528723B (zh) 2013-04-10
EP2074108B3 (en) 2013-06-26
WO2008036247A8 (en) 2008-06-26
EP2581366A1 (en) 2013-04-17
RS52679B (sr) 2013-06-28
SI2074108T1 (sl) 2013-04-30
US20120225906A1 (en) 2012-09-06
AU2007297729A1 (en) 2008-03-27
ES2400009T3 (es) 2013-04-05
CN101528723A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
MX2009002740A (es) Inhibidores de renina.
WO2008036216A8 (en) Piperidine derivatives as renin inhibitors
SG169983A1 (en) Aspartic protease inhibitors
MX2009003763A (es) Inhibidores de metaloproteasa derivados de heterociclicos.
GEP20094679B (en) Dipeptidyl peptidase inhibitors
MX2010008523A (es) Inhibidores macrociclicos de serina proteasa.
WO2006089005A3 (en) Combination of selective factor viia and/or xia and plasma kallikrein inhibitors
UA93375C2 (ru) Ингибиторы протеинкиназ ha ochobe замещенных амидов
TW200603798A (en) Disalt inhibitors of il-12 production
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
ZA200806778B (en) N-Hydroxyacrylamide compounds
GEP20125683B (en) Serine proteases inhibitors for hcv infections treatment
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MY157116A (en) Novel seh inhibitors and their use
MX2009010205A (es) Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
NO20064306L (no) Laktamer som konformasjonelt begrensede peptidomimetiske inhibitorer
WO2009148600A8 (en) Deuterated lysine-based compounds
WO2005063742A3 (en) Amidino compounds as cysteine protease inhibitors
WO2006102243A3 (en) Alpha ketoamide compounds as cysteine protease inhibitors
MX2009003563A (es) Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.
UA85701C2 (ru) Способ получения ингибиторов триптазы
WO2009067225A3 (en) Boceprevir derivatives for the treatment of hcv infections
MX2007011739A (es) Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.

Legal Events

Date Code Title Description
FG Grant or registration